2026 ISPE Annual Meeting

The 2026 ISPE Annual Meeting is taking place in Milan, Italy, from August 29–September 2, showcasing a wide array of Sentinel-related work through presentations and posters. The materials from each session will be available below following the conference.

Oral Presentation

• Assessing the Performance of Major Congenital Malformations as a Composite Outcome in Signal Detection and Evaluation
• Tree-Based Safety Signal Identification for Infliximab Biosimilar vs Reference Products

Posters

• Burden of Cutaneous Lupus Erythematosus in Commercial vs. Publicly Insured Patients in the FDA’s Sentinel Distributed Database
• Combining Treatment Propensity Scores and Clone-Censor-Weighting to Evaluate Treatment Duration in Active Comparator Studies
• A Descriptive Analysis of Weight Loss Medication Use, Including GLP-1 RA Products, and Intentional Self-Harm among Patients with Obesity in FDA's Sentinel Distributed Database
• Development and Evaluation of Targeted Outcome Trees for Safety Surveillance using Tree-Based Scan Statistics in the Sentinel System
• Dihydropyrimidine Dehydrogenase Gene Testing and Fluoropyrimidine Treatment in the United States – a Sentinel Distributed Database Study
• Evaluating Data-driven Automated Discovery of Disconnected Negative Controls Using Plasmode Simulations
• Finding Needles in the Same Haystack: Comparing Designated Medical Event vs Untargeted Approach in Signal Identification
• Mycophenolate Use During Pregnancy: An Analysis in the Sentinel Database
• Prevalence of Cutaneous Lupus Erythematosus in U.S. Pediatric and Adult Populations Using the FDA’s Sentinel Distributed Database
• Risk of Intentional Self-Harm After GLP1-RA Use Among Patients with Diabetes in FDA’s Sentinel Distributed Database
• Risk of Renal Cell Carcinoma Following At Least 180 Days of Exposure to Canagliflozin in U.S. Patients with Type 2 Diabetes Mellitus

More information on the conference can be found here.